FindTrial
Sign In

Comparative study of Similimum with Calcarea Fluorica 6C in cases of Osteoarthritis

Efficacy of Similimum compared with Calcarea Fluorica 6C (Organ Remedy based on Tissue Affinity) in patients of Osteoarthritis (Grade: 2 to 4) of knee joints using WOMAC Index as an Assessment Tool

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034807
Enrollment
120
Registered
2021-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M17- Osteoarthritis of knee

Interventions

Intervention1: Homoeopathic Similimum: Dose 30, 200, 1M, 10M Frequency - 1 dose to 7 dose Route - Orally Duration - 3 months Potency & Frequency of dose will be select on susceptibilty & sensitivity o

Sponsors

Dr Akshaykumar Mohanlal Patel
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Chronic as well as acute dimension of cases. 2. Patient of both sexes and age above 45yrs. 3. Patient diagnosed clinically with OA based on symptoms of Pain, stiffness, swelling & deformity. 4. Radiological diagnosed Osteoarthritis (Grade 2 to 4) will be taken. 5. Patient of any kind of occupation with any kind of life style.

Exclusion criteria

Exclusion criteria: 1. Clinically evident cases other than Osteoarthritis. 2. Patient who requires emergency medical treatment.

Design outcomes

Primary

MeasureTime frame
Similimum will be more effective than calc fluorica 6c in the cases of OA Timepoint: 2 Years 6 Months—

Secondary

MeasureTime frame
To understand the type the cases where Calc Fluorica 6C will be more effective. Timepoint: 2 Years 6 Months—

Countries

India

Contacts

Public ContactDr Akshaykumar Mohanlal Patel

Smt. Malini Kishore Sanghvi Homoeopathic Medical College & Hospital

ami.majmundar@gmail.com9925039779

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026